Background. Concerns exist whether monovalent (RV1) and pentavalent (RV5) rotavirus vaccines provide adequate protection against diverse strains and whether vaccine introduction will lead to selective pressure.
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Methods. We systematically reviewed vaccine effectiveness (VE) studies and classified strains as (1) homotypic: both G-and P-type antigen of the circulating strain were in the vaccine; (2) partially heterotypic: either the G-or P-type antigen of the circulating strain was in the vaccine; and (3) fully heterotypic: neither G-or P-type antigen of the circulating strain was in the vaccine. Some RV5 studies reported VE against the G-and the P-type component separately and could not be discreetly classified into the three categories. To make complete use of the data, we included these strains in our analysis, classifying them either as (1) single antigen (SA) vaccine-type; or (2) SA nonvaccine-type. We estimated pooled odds ratios using random effect regression models, and tested for differences in strain-specific VE. Strain distribution trends were assessed from surveillance reports.
Results. In high income countries, RV1 pooled VE (95% CI) was 94% (80-98), 71% (39-86), and 87% (76-93) against homotypic, partially heterotypic, and fully heterotypic strains, respectively. RV5 VE was 83% (78-87), 82% (70-89), 82% (70-89) and 75% (47-88) against homotypic, SA vaccine-type, partially heterotypic, and SA nonvaccine-type strains, respectively.
In middle income countries, RV1 pooled VE was 59% (36-73), 72% (58-81), and 47% (28-61) against homotypic, partially, and fully heterotypic strains, respectively. RV5 VE was 70% (58-78) against SA vaccine-type, 37% (10-56) against partially heterotypic strains and 87% (38-97) against SA nonvaccine-type. We found no evidence of a difference in VE for either vaccine in any setting (all p < 0.05) Prevalent strains in RV1 countries were G2P[4] (50%) and G1P[8] (22%), compared with G1P[8] (33%) and G2P[4] (30%) in RV5 countries. Sustained predominance of a single strain was not observed.
Conclusion. RV1 and RV5 exert similar effectiveness against homotypic and heterotypic strains. We found no evidence for persistence of specific strains indicating vaccine-induced selective pressure.
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